Intraperitoneal Versus Intravenous CPT-11 Given Intra- and Postoperatively for Peritoneal Carcinomatosis in a Rat Model

被引：0
|
作者：
Arndt Hribaschek
Roger Kuhn
Matthias Pross
Frank Meyer
Jörg Fahlke
Karsten Ridwelski
Carsten Boltze
Hans Lippert
机构：
[1] University Hospital,Department of Surgery
[2] Municipal Hospital,Department of Surgery
[3] University Hospital,Department of Pathology
来源：
Surgery Today | 2006年 / 36卷
关键词：
CPT-11; Peritoneal carcinomatosis; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：57 / 62
页数：5
相关论文
共 22 条
  • [1] Intraperitoneal versus intravenous CPT-11 given intra- and postoperatively for peritoneal carcinomatosis in a rat model
    Hribaschek, A
    Kuhn, R
    Pross, M
    Meyer, F
    Fahlke, J
    Ridwelski, K
    Boltze, C
    Lippert, H
    SURGERY TODAY, 2006, 36 (01) : 57 - 62
  • [2] Intraperitoneal versus intravenous CPT-11 for peritoneal seeding and liver metastasis
    Maruyama, M
    Nagahama, T
    Yuasa, Y
    ANTICANCER RESEARCH, 1999, 19 (5B) : 4187 - 4191
  • [3] Beneficial intraperitoneal (IP) versus intravenous (IV) application of CPT-11 to reduce tumor spread in experimentally induced peritoneal carcinomatosis
    Hribaschek, A
    Meyer, F
    Halangk, W
    Lippert, H
    Ridwelski, K
    GASTROENTEROLOGY, 2002, 123 (01) : 11 - 11
  • [4] 5-FU and Cpt-11 significantly reduce intraperitoneal tumor growth in experimental investigations of peritoneal carcinomatosis
    Hribaschek, Arndt
    Meyer, Frank
    Pross, Matthias
    Ridwelski, Karsten
    Schneider-Stock, Regine
    Lippert, Hans
    GASTROENTEROLOGY, 2006, 130 (04) : A900 - A901
  • [5] 5-FU and CPT-11 significantly reduce intraperitoneal tumor growth in experimental investigations of peritoneal carcinomatosis
    Hribaschek, A.
    Meyer, F.
    Pross, M.
    Ridwelski, K.
    Schneider-Stock, R.
    Lippert, H.
    ANNALS OF ONCOLOGY, 2006, 17 : 46 - 46
  • [6] Prevention and treatment of peritoneal carcinomatosis in experimental investigations with CPT-11 and oxaliplatin
    Hribaschek, A
    Pross, M
    Kuhn, R
    Krüger, S
    Ridwelski, K
    Halangk, W
    Boltze, C
    Lippert, H
    ANTI-CANCER DRUGS, 2002, 13 (06) : 605 - 614
  • [7] Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration
    Ahn, Byung-Jin
    Choi, Moon Ki
    Park, Young Suk
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lim, Ho Yeong
    Kang, Won Ki
    Ko, Jae-Wook
    Yim, Dong-Seok
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (12) : 1235 - 1245
  • [8] Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration
    Byung-Jin Ahn
    Moon Ki Choi
    Young Suk Park
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Ho Yeong Lim
    Won Ki Kang
    Jae-Wook Ko
    Dong-Seok Yim
    European Journal of Clinical Pharmacology, 2010, 66 : 1235 - 1245
  • [9] POPULATION PHARMACOKINETICS OF CPT-11 ( IRINOTECAN) IN GASTRIC CANCER PATIENTS WITH PERITONEAL METASTASIS AFTER INTRAPERITONEAL ADMINISTRATION.
    Ahn, B.
    Choi, M.
    Park, Y.
    Lee, J.
    Park, S.
    Park, J.
    Lim, H.
    Kang, W.
    Heo, J.
    Ko, J.
    Lee, J.
    Yim, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S87 - S87
  • [10] Intraperitoneal treatment using Taxol is effective for experimental peritoneal carcinomatosis in a rat model
    Hribaschek, A
    Ridwelski, K
    Pross, M
    Meyer, F
    Kuhn, R
    Halangk, W
    Boltze, C
    Lippert, H
    ONCOLOGY REPORTS, 2003, 10 (06) : 1793 - 1798
123